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Abstract
Background: Foot–and–mouth disease (FMD) is an economically devastating disease that severely limits international
trade of animals. Of the seven FMD virus (FMDV) serotypes, serotype A is one of the most widespread cross the world.
Currently antibodies to FMDV are detected in animals using the virus neutralization test (VNT) and the enzyme-linked
immunosorbent assay (ELISA). The VNT is laborious, time–consuming and reliant on live virus and cell cultures, while
ELISA has the advantage of using inactivated antigens and often provides more reproducible results. The aim of this
study was to develop a reliable and rapid competitive ELISA (cELISA) for the detection of antibodies to FMDV serotype
A (FMDV/A).
Results: A panel of FMDV/A specific monoclonal antibodies (mAbs) was generated and their ability to compete with a
polyclonal serum from FMDV/A–infected cattle was examined. Two mAbs inhibited the binding of a polyclonal serum
to FMDV/A viruses. The binding epitopes of each were determined as conformational and located on the VP2 viral
capsid protein. The FMDV/A cELISA was developed using these two mAbs and FMDV/A inactivated virus as antigen.
The diagnostic specificity and sensitivity were 99.7 and 99.3% (98.5–100%) respectively, based on a predetermined
cut–off of 50% inhibition. When analysing sera from animals experimentally infected with FMDV/A, the cELISA detected
antibodies from 5-days post infection (dpi) and remained positive for at least 21–28 days post infection. Comparison
based on the Kappa coefficient showed strong agreement (90–94%) between cELISA and VNT.
Conclusion: The cELISA results are comparable to the VNT for antibody detection making it a simple and reliable test
to detect antibodies against FMDV/A.
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Background
Foot–and–mouth disease (FMD) is one of the most highly
contagious animal diseases with a broad host range,
including cattle, buffaloes, pigs, sheep, goats and around
70 wildlife species. It is an economically devastating dis-
ease that severely constrains international trade of ani-
mals. The FMD virus (FMDV) is a non–enveloped virus
containing a single–stranded RNA genome surrounded by
an icosahedral capsid. The capsid comprises 60 copies
each of four structural proteins: VP1, VP2, VP3 and VP4
[1]. There are seven serotypes of FMDV namely O, A,
Asia 1, C, Southern African Territories (SAT) 1, SAT 2
and SAT 3. Outbreaks due to FMDV serotype A (FMDV/
A) have been reported in all continents, including South
Eastern Asia, Southern Asia, South America, Middle East,
Eastern and Western Africa [2]. Within FMDV/A, strains
are both antigenically and genetically diverse [3, 4]. A total
of 26 regional genotypes within three continental topo-
types have been reported for FMDV/A [5, 6].
Serological tests of FMDV are used for certification of
animals prior to import and export, confirmation of
FMDV infection and demonstration of vaccine efficacy
[7]. One of the international standard tests for FMDV
antibody detections is the virus neutralisation test (VNT).
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However, the VNT is costly and labour intensive render-
ing large scale serological testing difficult. In addition, the
procedure requires live virus, thus confining the test to
biocontainment level 3 laboratories in non–endemic
countries. Competitive ELISAs (cELISAs) are commonly
used for antibody detection due to their sensitivity, sim-
plicity, ease to scale up to accommodate the screening
of large numbers of serum samples and suitability to
detect antibodies from different species without need-
ing species–specific secondary antibodies [8, 9]. The
use of mAbs in these tests provides a consistent supply
of reagents that unlike polyclonal antisera, does not re-
quire the use of virus once mAbs have been generated.
Several cELISAs to detect antibodies against FMDV
non–structural protein (NSP) have been developed, val-
idated and used in serological surveillance [9–13].
However, NSP ELISAs are serotype–independent and
cannot be used in testing vaccine potency or monitoring
the effectiveness of vaccinations. cELISAs can also be used
post outbreak surveillance due to their specificity.
Ko et al. [14] reported a cELISA for anti-FMDV/A
antibody detection using a monoclonal antibody (mAb)
that was raised by immunization of mice with a VP1
peptide corresponding to the GH loop. The mAb used
in that study demonstrated reactivity to two FMDV/A
isolates (A24 Cruzeito/Brazil/55 and A22 Iraq) [14], but
its reactivity to other strains, especially recent isolates,
has not been examined. Furthermore, since the mAb
was raised against a region that is known for its high
variability, there is a possibility that the cELISA may not
detect antibodies against all FMDV/A isolates.
The goal of this study was to generate mAbs and de-
velop a simple and rapid serodiagnostic assay for FMDV/
A, suitable for testing sera from all susceptible species ex-
posed to a range of FMDV/A isolates. A FMDV/A cELISA
based on two mAbs that recognize a surface antigenic site
was developed and validated using serum samples from
experimentally infected animals. The cELISA is suitable
for use in diagnosis of FMDV/A infection, monitoring the
effectiveness of field vaccinations, and epidemiological
studies of FMD in animal populations.
Results
Production and characterization of mAbs against FMDV/A
Spleen cells from mice inoculated with BEI–inactivated
FMDV/A22 Iraq 24/64 (A22 Iraq) were fused with mye-
loma cells. Twelve hybridomas specific for FMDV/A
were generated from three fusions. After subcloning, the
ability of the mAbs to compete with a polyclonal serum
from cattle infected with FMDV/A was examined. Two
mAbs (#5 and #7) clearly inhibited the binding of the
polyclonal antibodies to FMDV/A. These two mAbs
were characterized as IgG2a/k and IgG1/k respectively.
The reactivity and specificity of the mAbs against
different FMDV serotypes and other viruses causing
vesicular disease were tested using a double antibody
sandwich (DAS) ELISA [15]. Results indicated that
mAb #7 was FMDV/A specific without cross–reactivity
to other serotypes of FMDV or other vesicular disease
viruses (Additional file 1: Table S1). However, mAb #5
showed cross–reactivity to four FMDV/C isolates (data
not shown).
The reactivity of the two mAbs to different field iso-
lates of FMDV/A was examined. The mAb #5 reacted
with all 46 field isolates archived at the National Centre
for Foreign Animal Disease (NCFAD) indicating the
binding epitope of mAb #5 is conserved (Fig. 1a). In
contrast, mAb #7 failed to react with five of 46 FMDV/
A isolates (A/IRN56/99, A/ARG2/01, A/IRN5/03, A/
COL/85 and A/ARG/87) (Fig. 1b). Relatively low binding
affinity (with optical density (OD) < 0.55) was observed
for mAb #5 with two isolates and for #7 with two iso-
lates (Fig. 1). To characterize the mAb–binding sites,
their reactivity against native and denatured FMDV/A
was examined using an indirect ELISA. Both mAbs
failed to react with the denatured FMDV/A, indicating
that their binding sites were conformational (data not
shown).
Identification of mAb–binding sites using mAb resistant
mutant selection and sequencing
The mAb resistant mutant selection technique was used
to identify the binding sites of the two mAbs on the sur-
face of viral particles. The reactivity of the two mAbs to
the matching mutants demonstrated a gradual decline,
until it was undetectable at passage six, indicating that
the mAb binding sites were fully depleted in the selected
mutants (data not shown).
The sequences of P1 region that encodes capsid proteins
(VP1, VP2, VP3 and VP4) were determined for two mAb
escape mutants, and compared with that of parental
FMDV/A22 Iraq.
In both escape mutants, the mutations were observed
in VP2. The mutant selected using mAb #5 contained
two amino acid substitutions Gln79 to Lys and a Lys80
to Thr, while, the mutant selected using mAb #7 had
amino acid substitutions His77 to Arg, and Lys80 to
Thr. These substitutions are located in the external part
of viral particles and are adjacent to antigenic sites 1
(G142→Q157) and sites 3 (E82→K88) as previously
identified [16, 17] (Fig. 2a). Amino acid sequence align-
ments of the A22 Iraq VP2 with those of representative
viruses from the other 6 serotypes revealed amino acids
are highly variable in the region near the antigenic site 3
of FMDV/A (Fig. 2b). The VP2 alignments of all 46 sero-
type A isolates indicated that amino acid (aa) at position
80 is highly conserved, whilst at position 77, (ETH/6/
2000, GHA/4/1996 and IRN/1/1996) had an amino acid
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substitution of His to Tyr; the isolate (COL/85) had an
amino acid change of His to Glu, and another isolate
(ARG/87) had a change of His to Asp.
Examination of VP2 sequences of 45 FMDV/A isolates
with that of A22 Iraq revealed various unique amino acid
substitutions at or near mAb #7 binding sites for the five
non-binding isolates to mAb #7. These substitutions are:
an Asp→Asn at position 72 for A/IRN/56/1999; Glu→
His at position 79 and Lys→His at position 88 for A/
ARG/2/2001; Thr→Val at position 85 for A/IRN/5/2003;
His→Glu at position 77, Thr→ Ser at position 85, and
Lys→Asn at position 88 for A/COL/85; His→Asp at
Fig. 1 Reactivity of the two mAbs against different FMDV/A isolates in a DAS ELISA. A rabbit antiserum pool to different topotypes of FMDV/A
was coated onto microtitre plates. Thereafter, FMDV/A isolates were added to the plates and detected with the mAb #5 (a) and #7 (b). The lines
at the OD value of 0.55 are indicated
Fig. 2 Antigenic sites identified in the capsid crystal structure of the FMDV/O1 BFS 1860. a The O1 BFS 1860 asymmetric unit (PDB # 1FOD) was
manipulated with Chimera, consisting of 1 VP1 (yellow), 1 VP2 (green), 1 VP3 (cyan) and 1 VP4 (tan), with previously identified antigenic sites
shown as blue spheres (site 1), orange spheres (site 2), gray spheres (site 3), black spheres (site 4) and magenta spheres (site 5), and with A22 Iraq
escape mutant mutations (H77R, Q79K and K80T) depicted as red spheres, respectively. b Partial amino acid alignment of the VP2 sequences of
representative FMDV serotypes. Positions of the FMDV/A22 Iraq escape mutant mutations are indicated as red dots and the adjacent FMDV/A
antigenic site 3 is shown in a box
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position 77 and Lys→His at position 88 for A/ARG/87.
All these substitutions are surface-exposed residues when
viewed in the 3D structure of FMDV/A.
Development of the FMDV/A cELISA
A cELISA to detect antibodies against FMDV/A was
developed using the two FMDV/A specific mAb mixture
and optimized with a serum of known titres. The BEI
inactivated FMDV/A24 Cruziero was used as antigen in
the cELISA, since there was no significant difference as
compared to A22 Iraq (data not shown).
To determine the assay specificity, a total of 1,174
negative sera were tested. The frequencies of the per-
centage of inhibition (% inhibition) generated from these
sera had a normal distribution (mean −1.14%, standard
deviation 14.15; Fig. 3). The cut–off value was deter-
mined as <50% inhibition [18]. Three of the samples
exceeded this cut–off value, which produced a diagnostic
specificity of 99.7%.
Evaluation of the FMDV/A cELISA using sera from
experimentally infected animals
The antibody responses to FMDV/A in sera from experi-
mentally infected cattle, sheep and pigs (A24 Cruzeiro
or A22 Iraq) collected at various days post inoculation
(dpi) were examined using the FMDV/A cELISA. Anti-
body responses were negative from 0 to 4 dpi (Fig. 4a).
At 5 dpi all serum samples were positive for antibodies
to FMDV/A, and remained positive until the end of the
experiments (21–28 dpi). The FMDV/A cELISA were
compared with the gold standard serological test VNT
using 99 serial blood samples from eight animals. The
Cohen’s Kappa is 0.977 with 95% CI of 0.93–1.0, which
indicates a strong agreement (94%) between the cELISA
and VNT (Fig. 4b).
Sera from eighteen sheep infected with FMDV/A
Vietnam/15/12 were tested to evaluate the ability of the
FMDV/A cELISA to detected antibodies against a con-
temporary isolate. Antibodies were detected in 83.3% of
the sheep at 5 dpi and 100% at 6 dpi (Fig. 5a). The
calculated diagnostic sensitivity of A/cELISA was 99.3%
(98.5–100%). Similar results were observed for VNT. A
scatter plot of cELISA% inhibition against VNT titres
for 180 serial blood samples from 18 animals is shown
in Fig. 5b. The Cohen’s Kappa is 0.90 with 95% CI of
0.71–0.89, which indicates a strong agreement (90%)
between the cELISA and VNT. However, the correla-
tions between cELISA and VNT for a few samples col-
lected early after infection (4–6 dpi) were not as good
as samples collected at other times.
To determine cross–reactivity, the FMDV/O positive
sera from sheep vaccinated and challenged with FMDV/
O [19] were tested using the FMDV/A cELISA. The
results showed no cross–reactivity up to 35 days post
challenge (data not shown). However, there was cross–
reactivity (25–30%) with sera from experimental inocu-
lated animals using FMDV serotype O, Asia1, C, SAT 2
and SAT 3.
Discussion
The purpose of this study was to produce FMDV/A–
specific mAbs and use them to develop a cELISA for the
detection of FMDV/A antibody. A panel of FMDV/A
specific mAbs was successfully generated, two of which
competed with a polyclonal serum from FMDV/A in-
fected cattle in a cELISA. The binding sites of the two
mAbs were determined to be conformational epitopes
exposed on the surface of VP2, located at amino acid
positions 77–80, adjacent to antigenic sites 1 (G142→
Q157) and 3 [16, 17]. These sites are known to be im-
munologically important for FMDV serotype O, A and C
[17, 20, 21]. In addition, it has been shown that amino
acids 70–80 of VP2 are located in close proximity to the
VP1 G–H loop [22]. Mutations within these sites can
affect the antigenicity of FMDV. These results suggest
that variations at amino acids 70–80 of VP2 domains
could be important to the antigenic diversity of FMDV
in addition to the hyper–variable VP1 G–H loop (aa
140–160). Being an immune–dominant site increases
the chances that a serological assay based on this region
will be sufficiently sensitive.
A FMDV/A cELISA using a mAb produced with a
VP1 peptide corresponding to the G–H loop was re-
ported previously [14]. However, evaluation of the re-
activity of the mAb was limited to two FMDV/A
isolates in that study. Therefore, the reactivity of the
Fig. 3 Frequency distribution of the negative sera tested using the
FMDV/A cELISA. Serum samples were collected from disease–free
bovine (n = 320), porcine (n = 475) and ovine (n = 379) in Canada.
Rabbit polyclonal anti–FMDV/A serum pool was coated onto
microtitre plates, thereafter BEI inactivated FMDV/A antigen was
added. Equal volumes of diluted sera and mAbs (#5 and #7) were
added to the plates and allowed to compete with antibodies in
serum samples. Results are expressed as the percentage of inhibition
Yang et al. Virology Journal  (2016) 13:195 Page 4 of 9
mAb to other isolates including recent outbreak isolates
is not known. Considering that VP1 is the most variable
FMDV structural protein [23, 24], it is highly likely that
recent isolates of FMDV/A might not react with mAbs
produced with VP1 of older isolates. In contrast, there
is less divergence and variation in FMDV VP2 and VP3
structural proteins [17]. Conservation of the binding
epitopes of FMDV mAbs is an important factor in the
choice of appropriate mAbs for diagnostic assays.
Therefore, the fact that the two mAbs reacted to the
antigenically dominant VP2 of FMDV renders them
ideal for a FMDV/A cELISA. The mAb #5 recognized a
highly conserved epitope and reacted to 46 FMDV/A
isolates, including recent outbreak isolates from 2007
to 2012.
The mAb #7 failed to react with five of the 46 FMDV/
A isolates. Examination of VP2 sequences of 45 FMDV/
A isolates with that of A22 Iraq revealed various unique
amino acid substitutions at or near mAb #7 binding sites
for the five non-binding isolates to mAb #7. All substitu-
tions are surface-exposed residues when viewed in the
3D structure of FMDV/A. Thus, it is likely that amino
acid alterations may affect binding of mAb # 7 to these
five isolates.
Fig. 4 Comparison of FMDV/A cELISA and VNT using sera from FMDV/A experimentally infected animals. “S”, “C” and “P” samples correspond to
sera from sheep, cattle and pigs. The samples, S68 and S692 were infected with A22 Iraq, others with A24 Cruzeiro. Sera were collected daily up
to 10 days post infection (dpi), and then at 7 days intervals after 10 dpi. a Serial blood samples were diluted (1:10) and tested using FMDV/A
cELISA, and (b) scatter plot representing the percentage of inhibition in cELISA versus VNT titres for 99 serial blood samples from eight animals.
The line is fitted by linear regression (r2 = 0.78, p < 0.0001)
Fig. 5 Comparison of A/cELISA and VNT using sera from FMDV/A Vietnam/15/2012 infected sheep. Sheep (n = 18) were coronary band infected.
Sera were collected daily during the course of experiments. a Serial blood samples were diluted (1:10) and tested using FMDV/A cELISA, and (b)
scatter plot representing the percentage of inhibition in cELISA versus VNT titres for180 serial blood samples from eighteen animals. The line is
fitted by linear regression (r2 = 0.81, p < 0.0001)
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There were no observed amino acid substitutions at
the mAb binding sites for the low–binding isolates. A
possible explanation for the poor binding may be that
other mutations occurred that changed the conform-
ational structure of the mAb binding sites, thus affecting
the mAbs’ binding.
Since FMDV/A is the most antigenically diverse of the
seven serotypes [5], the pair of monoclonal antibodies
reacting to different antigen sites is necessary to increase
the chance of detecting of antibodies to all strains of
FMDV/A, and reduce cross–reactivity with other FMDV
serotypes.
The FMDV/A cELISA consistently detected antibodies
to FMDV/A in FMDV/A infected animal of different
species and was comparable to the gold standard VNT
for antibody detection. The Cohen’s Kappa was 0.80–
0.977 with strong agreements (90–94%) between the
cELISA and VNT indicating the potential use of the
cELISA instead of VNT for large screening. However the
correlations between cELISA and VNT for a few samples
collected early after infection (4–6 dpi) were not as good
as samples collected at other times. VNTs detect neutral-
izing antibody activity and ELISA may detect different
antibody subsets. The poor correlation may because of in-
dividual variation after FMDV inoculation. Vratskikh et al.
[25] provide evidence for extensive differences in the spec-
ificities and relative proportions of antibody populations
induced by yellow fever vaccination in different individ-
uals. Furthermore, substantial variation was found in the
ratio between virion ELISA reactivities and neutralization
titers, suggesting a strong influence of antibody subset
composition of individual sera. Unlike the VNT, cELISA
does not provide antibody titres which are important for
post–vaccine monitoring.
The diagnostic specificity of this FMDV/A cELISA was
99.7%, which was comparable to a previously reported
FMDV/A cELISA [14]. There was no cross–reactivity
when testing sera from FMDV/O1 Manisa vaccinated/
challenged sheep in the FMDV/A cELISA. However,
there was cross–reactivity with sera from experimental
inoculated animals using FMDV serotype O, Asia1, C,
SAT 2 and SAT 3. Similar to previous finding where
cross–reactions were observed using a FMDV/O cELISA
when testing sera collected from animals vaccinated and
challenged with FMDV A, C and Asia1 [26]. A blocking
ELISA for FMDV/A was found to cross–react strongly
with serum positive for antibodies to FMDV/Asia 1 [14].
Hedger et al. [27] found that animals undergoing natural
infection with one type of FMDV (type O) had equal or
even higher serum antibody titres against one or more
of the other types tested (types A, C, Asia 1 and SAT 1).
Thus, it remains unclear whether the cross-reactivity
among serotypes is caused by low assay specificity, or
heterotypic humoral responses following virus infections
[28]. Though cross–reactivity among FMDV serotypes
is undesirable, it is preferable when sensitivity is the
aim. When testing vaccinated populations, these cross-
reactions are not of great concern since the serotype of
the vaccine strain should be known.
Conclusion
A panel of FMDV/A specific mAbs was generated and
two mAbs specific for antigenically dominant sites lo-
cated on the structural proteins VP2 were used in the
development of a simple and reliable FMDV/A cELISA
for the detection of FMDV/A–specific antibodies. The
major improvement this FMDV/A cELISA offers over
similar assays published previously [14] is the use of




All FMDV viruses used in this study were provided by the
FAO/OIE World Reference Laboratory for FMD (Pirbright
Institute, Pirbright, UK) and listed in Additional file 1:
Table S1. The viruses were amplified using either Baby
hamster kidney–21 (BHK) or Mengeling–Vaughn porcine
kidney (MVPK) cells [29] cultured in Alpha Modification
of Eagle’s medium (AMEM; WISENT Inc. Canada).
Culture supernatants were harvested and clarified upon
observation of complete cytopathic effect (CPE). For
immunization, virus was inactivated with 2–Bromoethyla-
mine Hydrobromide (BEI, Sigma-Aldrich, USA) and
purified as previously described [8].
Generation and purification of monoclonal antibodies
Mouse inoculation and hybridoma production were
performed as previously described [8]. Briefly, mice
were immunized using BEI inactivated FMDV/A22 Iraq
three times at 4 week intervals. Spleen cells from immu-
nized mice were then fused with myeloma cells (P3X63
Ag8.653, ATCC, Rockville, MD, USA). Hybridoma super-
natants were selected using a FMDV/A double antibody
sandwich (DAS) ELISA. FMDV/A antibody positive
clones were subcloned, the isotype determined using a
mouse monoclonal antibody isotyping kit (Roche, Indian-
apolis, IN, USA) and the antibodies purified as previously
described [30].
ELISAs
DAS ELISAs for hybridoma screening, mAbs’ specificity
and cross–reactivity testing were performed as previ-
ously described [15].
An indirect ELISA was used to characterize the mAbs’
binding epitopes. The ELISA and virus denaturation was
performed as previously described [15]. Briefly, microtitre
plates (Nunc Maxisorp®, ThermoFisher Sientific, Rochester,
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NY, USA) were coated with purified and denatured
FMDV/A diluted in 0.1 M bicarbonate, pH 8.3 and in-
cubated overnight at 4 °C. The plates were blocked with
5% skim milk in a washing buffer (0.05% Tween20 in
0.01 M phosphate–buffered saline (PBS–T)) at 37 °C.
After incubation, hybridoma culture supernatants were
added to the plates. Then a horse–radish peroxidase
(HRP)–conjugated goat anti–mouse IgG (Jackson Immu-
noResearch Laboratories Inc., West Grove, PA, USA) was
added. For detection, 2, 2′–Azino diethylbenzothiazoline
sulfonic acid substrate (ABTS, Roche) was added and
the OD at 405 nm was measured using a plate reader
(Photometer Multiskan Reader, Labsystems). Each incu-
bation step was 1 h at 37 °C and followed by washing
three times with the washing buffer.
Isolation of mAb–resistant mutants
FMDV/A22 Iraq (107 TCID50/ml) was mixed with puri-
fied mAbs #5 and #7 for 30min at 37 °C. The virus/mAb
mixture and virus only (control) were added onto MVPK
cells in T25 flasks. Each flasks were incubated at 37 °C
until 100% CPE was observed. The culture supernatants
were collected and clarified by centrifugation at 200 × g
for 5min. The collected virus was used for the next passage.
The procedure was repeated six times. The two mutants
were plaque–purified and analyzed [30].
Sequencing of the P1 region of mutant and parental
FMDV/A22 Iraq
The sequence was analyzed as previously described
[31]. Briefly, genomic RNA was extracted from parental
FMDV/A22 Iraq and its mutants. Available whole gen-
ome sequences of FMDV/A from GenBank were aligned.
Terminal oligonucleotide primers complementary to the
L gene (5′– TGYGTYACCTCYRAYGGKTGGT –3′)
(Invitrogen, Carlsbad, CA, USA) and 2B gene (5′–
GAAGAAGAARGGYCCRGGGTTGG –3′) were de-
signed for reverse transcription polymerase chain reaction
(RT–PCR). Additional primers for sequencing the whole
P1 region were chosen from the most conserved region of








cDNA of the P1 regions of each virus were synthesized
from genomic RNA followed by further PCR amplification
of the cDNAs. Sequencing was performed in both di-
rections using an ABI Prism BigDye Terminator v3.1
Cycle Sequencing Ready Reaction kit (Applied Biosystems,
Carlsbad, California, USA) and an Applied Biosystems
Genetic Analyzer DNA Model 3130X. Pairwise nucleotide
sequence alignments were performed using the Martinez–
NW method [32] and the Lipman–Pearson method for
protein alignments [33].
Identification of the monoclonal antibody binding sites
on the 3D structural model of VP2
Amino acid sequences of the mutant FMDV/A22 Iraq
VP2s were aligned with those of FMDV/O1 BFS 1860
VP2 to identify relative locations of the FMDV/A22 Iraq
mutations in the crystal structure of the FMDV/O1 BFS
1860 (PDB # 1FOD; [34]). A molecular graphics image
was produced using the UCSF Chimera package from
the Resource for Biocomputing, Visualization and Inform-
atics at the University of California, San Francisco [35]
and the resulting images imported into Adobe Photoshop
for editing.
Development of a cELISA for detection of serum FMDV/A
antibodies using the FMDV/A monoclonal antibodies
The two mAbs (#5 and #7) and BEI inactivated FMDV/
A antigen were used in the development of an FMDV/A
cELISA. Optimal antigen concentration and antibody
dilutions were determined by checkerboard titrations
using a serum raised against A24 Cruzeito. Briefly, mi-
crotitre plates were coated overnight at 4 °C with
100 μl/well of an antiserum which was pooled from rab-
bits infected with either one of the following FMDV/A
isolates: A24 Cruzeito, A22 Iraq, Iran 1/96 or Col/85.
Plates were washed five times with washing buffer,
followed by the addition of 100 μl of BEI inactivated
FMDV/A24 Cruziero diluted in buffer (2% normal bovine
serum and 2% normal rabbit serum in PBS–T) and incu-
bated at 37 °C for 1 h with agitation. After washing, 50 μl
of heat–inactivated test sera (final 1:10 dilution) in dupli-
cate, and an equal volume of the mixture of the two di-
luted mAbs were added to specific wells with the final
concentrations 9 ng/well and 35 ng/well for mAb #5 and
#7 respectively. Plates incubated for 1 h at 37 °C. After
further washing, 100 μl of HRP–conjugated goat anti–
mouse IgG (1:2000) was added and incubated for 1 h at
37 °C with agitation. Plates were washed again and
3,3′,5;–tetramethyl benzidine dihydrochloride substrate
(TMB, Sigma–Aldrich, St Lucia, MO, USA) added for
colour development. The reaction was stopped with the
addition of 50 μl/well of 2 M sulfuric acid after 15min in-
cubation at room temperature. The OD was determined
at 450 nm using a plate reader. For each washing step, the
plates were washed five times with the washing buffer.
Results were calculated based on strong positive (Q1)
and negative reference sera (Q3) using the following for-
mula: % inhibition = [(Q3 OD – test sample OD)/(Q3 OD
– Q1 OD)] × 100%.
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Negative and positive sera
Negative serum samples were collected from naïve cattle
(n = 320), pigs (n = 475) and sheep (n = 379) in Canada, a
FMD free–country. The positive sera (A24 Cruzeio and
A22 Iraq) were obtained from animals (cattle = 2, pigs = 2
and sheep = 4) experimentally infected with FMDV [10].
Additional sheep (n = 18) were infected with FMDV/A
Vietnam/15/2012 via the coronary band. Serum samples
were collected daily.
Virus neutralization test (VNT)
The VNT was performed with FMDVA22 Iraq and IBRS2
cells as described previously with modifications [7, 36].
Serum samples were heat inactivated (56 °C, 30min) be-
fore neutralization assays. Sera with titres >1.5 log10 (1:32)
were considered positive [7].
Data analysis
Cohen’s kappa coefficients were calculated to evaluate
interrater agreement between cELISA and VNT using
SAS.
Additional file
Additional file 1: Table S1. Viruses used in this study. (DOCX 17 kb)
Acknowledgments
The authors gratefully thank the animal care staff for expert animal services, the
FAO/OIE World Reference Laboratory for FMD, Pirbright Institute, Pirbright, UK
for providing the FMDV isolates; Kate Hole and Tim Salo for the preparation of
viruses and serum samples; Professor Depeng Jiang, University of Manitoba for
data analysis and interpretation.
Authors’ contributions
MY Conceived of the study, designed, coordinated, produced the mAbs and
drafted the manuscript; WX, performed virus mutant selection, sequence
analysis and edited the manuscript; HB, MG performed and validated the
cELISA; JH, WV participated in the animal study design, carried out animal
experiments and sample collections, writing and editing of the manuscript;
CN participated in the animal study design, writing and editing of the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval
The Animal Care Committee at the Canadian Science Centre for Animal and
Human Health approved the animal use in all the studies reported here. All
animal work was performed in compliance with the Canadian Council for
Animal Care guidelines.
Author details
1National Centre for Foreign Animal Disease, 1015 Arlington Street,
Winnipeg, MB R3E 3M4, Canada. 2Australian Animal Health Laboratory, CSIRO,
5 Portarlington Road, Geelong, VIC 3220, Australia.
Received: 16 September 2016 Accepted: 10 November 2016
References
1. Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev. 2004;
17(2):465–93.
2. King D, Henstock M. OIE/FAO FMD laboratory network annual report.
Pirbright: IAH; 2015.
3. Upadhyaya S, Ayelet G, Paul G, King DP, Paton DJ, Mahapatra M. Genetic
basis of antigenic variation in foot-and-mouth disease serotype A viruses
from the Middle East. Vaccine. 2014;32(5):631–8.
4. Bari FD, Parida S, Tekleghiorghis T, Dekker A, Sangula A, Reeve R, Haydon
DT, Paton DJ, Mahapatra M. Genetic and antigenic characterisation of
serotype A FMD viruses from East Africa to select new vaccine strains.
Vaccine. 2014;32(44):5794–800.
5. Knowles N, Nazem Shirazi M, Wadsworth J, Swabey K, Stirling J, Statham R,
Li Y, Hutchings G, Ferris N, Parlak Ü. Recent spread of a new strain (A‐Iran‐
05) of foot‐and‐mouth disease virus type A in the Middle East. Transbound
Emerg Dis. 2009;56(5):157–69.
6. Mohapatra JK, Subramaniam S, Pandey LK, Pawar SS, De A, Das B,
Sanyal A, Pattnaik B. Phylogenetic structure of serotype A foot-and-
mouth disease virus: global diversity and the Indian perspective.
J Gen Virol. 2011;92(Pt 4):873–9.
7. World Organisation for Animal Health. In: Office International des épizooties,
editor. Manual of diagnostic tests and vaccines for terrestrial animals
(mammals, birds and bees) [electronic resource]. Paris: Office International
des épizooties; 2008 [Anonymous].
8. Yang M, Clavijo A, Li M, Hole K, Holland H, Wang H, Deng MY. Identification
of a major antibody binding epitope in the non-structural protein 3D of
foot-and-mouth disease virus in cattle and the development of a
monoclonal antibody with diagnostic applications. J Immunol Methods.
2007;321(1–2):174–81.
9. Sørensen K, De Stricker K, Dyrting K, Grazioli S, Haas B. Differentiation of
foot-and-mouth disease virus infected animals from vaccinated animals
using a blocking ELISA based on baculovirus expressed FMDV 3ABC antigen
and a 3ABC monoclonal antibody. Arch Virol. 2005;150(4):805–14.
10. Yang M, Parida S, Salo T, Hole K, Velazquez-Salinas L, Clavijo A.
Development of a competitive enzyme-linked immunosorbent assay for
detection of antibodies against the 3B protein of foot-and-mouth disease
virus. Clin Vaccine Immunol. 2015;22(4):389–97.
11. Clavijo A, Wright P, Kitching P. Developments in diagnostic techniques for
differentiating infection from vaccination in foot-and-mouth disease. Vet J.
2004;167(1):9–22.
12. Bronsvoort BM, Parida S, Handel I, McFarland S, Fleming L, Hamblin P, Kock
R. Serological survey for foot-and-mouth disease virus in wildlife in eastern
Africa and estimation of test parameters of a nonstructural protein enzyme-
linked immunosorbent assay for buffalo. Clin Vaccine Immunol. 2008;15(6):
1003–11.
13. Mohapatra JK, Pandey LK, Sanyal A, Pattnaik B. Recombinant non-structural
polyprotein 3AB-based serodiagnostic strategy for FMD surveillance in
bovines irrespective of vaccination. J Virol Methods. 2011;177(2):184–92.
14. Ko YJ, Lee HS, Jeoung HY, Heo EJ, Ko HR, Chang BS, Joo HD, Gerelmaa
U, Dashzeveg B, Tserendorj S, Sodnomdarjaa R, Park JH, Kweon CH, Cho
IS, Paik SG. Use of a baculovirus-expressed structural protein for the
detection of antibodies to foot-and-mouth disease virus type A by a
blocking enzyme-linked immunosorbent assay. Clin Vaccine Immunol.
2010;17(1):194–8.
15. Yang M, Clavijo A, Suarez-Banmann R, Avalo R. Production and
characterization of two serotype independent monoclonal antibodies
against foot-and-mouth disease virus. Vet Immunol Immunopathol. 2007;
115(1–2):126–34.
16. Maree FF, Blignaut B, Esterhuysen JJ, de Beer TA, Theron J, O'Neill HG,
Rieder E. Predicting antigenic sites on the foot-and-mouth disease virus
capsid of the South African territories types using virus neutralization data. J
Gen Virol. 2011;92(Pt 10):2297–309.
17. Saiz JC, Gonzalez MJ, Borca MV, Sobrino F, Moore DM. Identification of
neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth
disease virus, defined by neutralization-resistant variants. J Virol.
1991;65(5):2518–24.
18. Jacobson RH. Validation of serological assays for diagnosis of infectious
diseases. Rev Sci Tech. 1998;17(2):469–526.
19. Horsington J, Zhang Z, Bittner H, Hole K, Singanallur NB, Alexandersen S,
Vosloo W. Early protection in sheep against intratypic heterologous
challenge with serotype O foot-and-mouth disease virus using high-
potency, emergency vaccine. Vaccine. 2015;33(3):422–9.
20. Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F, Parry NR. Neutralizing
epitopes of type O foot-and-mouth disease virus. I. Identification and
Yang et al. Virology Journal  (2016) 13:195 Page 8 of 9
characterization of three functionally independent, conformational sites. J
Gen Virol. 1989;70(Pt 6):1483–91.
21. Mateu MG, Hernandez J, Martinez MA, Feigelstock D, Lea S, Perez JJ, Giralt E,
Stuart D, Palma EL, Domingo E. Antigenic heterogeneity of a foot-and-
mouth disease virus serotype in the field is mediated by very limited
sequence variation at several antigenic sites. J Virol. 1994;68(3):1407–17.
22. Bolwell C, Brown AL, Barnett PV, Campbell RO, Clarke BE, Parry NR,
Ouldridge EJ, Brown F, Rowlands DJ. Host cell selection of antigenic variants
of foot-and-mouth disease virus. J Gen Virol. 1989;70(Pt 1):45–57.
23. Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F. The three-dimensional
structure of foot-and-mouth disease virus at 2.9 Å resolution. 1989.
24. Strohmaier K, Franze R, Adam KH. Location and characterization of the
antigenic portion of the FMDV immunizing protein. J Gen Virol.
1982;59(Pt 2):295–306.
25. Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U,
Roggendorf M, Roggendorf H, Allwinn R, Heinz FX. Dissection of
antibody specificities induced by yellow fever vaccination. PLoS Pathog.
2013;9(6):e1003458.
26. Chénard G, Miedema K, Moonen P, Schrijver RS, Dekker A. A solid-phase
blocking ELISA for detection of type O foot-and-mouth disease virus
antibodies suitable for mass serology. J Virol Methods. 2003;107(1):89–98.
27. Hedger R, Barnett I, Gradwell D, Travassos Dias P. Serological tests for foot-
and-mouth disease in bovine serum samples. Problems of interpretation.
Rev Sci Tech Off Int Epiz. 1982;1(2):387–93.
28. Wekesa SN, Sangula AK, Belsham GJ, Tjornehoj K, Muwanika VB, Gakuya F,
Mijele D, Siegismund HR. Characterisation of recent foot-and-mouth disease
viruses from African buffalo (Syncerus caffer) and cattle in Kenya is
consistent with independent virus populations. BMC Vet Res. 2015;11(1):1.
29. Dinka SK, Swaney LM, Vicar JW. Selection of a stable clone of the MVPK-1
fetal porcine kidney cell for assays of foot-and-month disease virus. Can J
Microbiol. 1977;23(3):295–9.
30. Yang M, Goolia M, Xu W, Bittner H, Clavijo A. Development of a quick
and simple detection methodology for foot-and-mouth disease virus
serotypes O, A and Asia 1 using a generic RapidAssay Device. Virol J.
2013;10:125-422X-10-125.
31. Yang M, Xu W, Goolia M, Zhang Z. Characterization of monoclonal
antibodies against foot-and-mouth disease virus serotype O and application
in identification of antigenic variation in relation to vaccine strain selection.
Virol J. 2014;11:136-422X-11-136.
32. Martinez HM. An efficient method for finding repeats in molecular
sequences. Nucleic Acids Res. 1983;11(13):4629–34.
33. Lipman DJ, Pearson WR. Rapid and sensitive protein similarity searches.
Science. 1985;227(4693):1435–41.
34. Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, Lea S,
Lewis R, Newman J, Parry N. Structure of a major immunogenic site on
foot-and-mouth disease virus. Nature. 1993;362(6420):566–8.
35. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
Ferrin TE. UCSF Chimera–a visualization system for exploratory research and
analysis. J Comput Chem. 2004;25(13):1605–12.
36. Golding SM, Hedger RS, Talbot P. Radial immuno-diffusion and serum-
neutralisation techniques for the assay of antibodies to swine vesicular
disease. Res Vet Sci. 1976;20(2):142–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yang et al. Virology Journal  (2016) 13:195 Page 9 of 9
